Outcome MeasureMystical Experience

EBI

Emotional Breakthrough Inventory

7 Papers in Blossom

Clinical Thresholds

630
Low breakthrough
Score 6–14
Moderate breakthrough
Score 15–22
High breakthrough
Score 23–30

Outcome Data Across Studies

Reported results for EBI across 6 studies with quantitative data.

Outcome data across 11 study arm–timepoint observations
SD
Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder
2023Exploratory
Visual Healing(experimental)0.167106.62.50.050
Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder
2023Exploratory
Standard setting(active_comparator)0.167107.51.60.050
Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation
2025Exploratory
Psilocybin-assisted treatment program(experimental)72371.026.3—
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression
2025Secondary
High dose(experimental)27957.232.0—
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression
2025Secondary
Medium dose(experimental)27448.028.0—
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression
2025Secondary
Low dose(experimental)27925.530.0—
A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience
2026Secondary
Psilocybin group therapy(experimental)313———
Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study
2026Exploratory
Psilocybin + therapy(experimental)15270.023.0—
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis
2026Secondary
Low dose(experimental)17938.024.4—
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis
2026Secondary
Medium dose(experimental)17454.424.6—

Papers Using EBI

Open Accessindividual

A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience

This Phase 1 study (n=13) tested a second group retreat psilocybin therapy session in people with metastatic cancer who had only partly responded before. It found no serious side effects, and anxiety and depression scores improved, with more participants reporting a full mystical experience after the second session.

Published
Authors
Back, A. L., McGregor, B. A., Thorn, L. L., Harvey, K., Blom, D., Callan, G., Guy, J., Kumar, S., Hershberg, R., Layer, M., Levin, J., Myers, S., Perez, J., Salmonson, K., Thompson, P., Whinney, J.
Paywallindividual

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis

This secondary analysis (n=79 of n=233) of a Phase II randomised trial examined whether therapeutic alliance or the psychedelic experience itself better predicted antidepressant outcomes in people with treatment-resistant depression (TRD) receiving psilocybin (25 mg), finding that measures of the psychedelic experience were more strongly associated with reduced depression scores than pre-dosing therapeutic alliance, though alliance did appear to modestly facilitate the quality of the psychedelic experience.

Published
Journal
Journal of Affective Disorders
Authors
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Carhart-Harris, R., Croal, M., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Kirlic, N., Licht, R. W., Marwood, L., Nowakowska, A., Páleníček, T., Repantis, D., Schoevers, R. A., Simmons, H., Soares, J. C., Somers, M., Tsai, J., Wahba, M., Williams, E., Young, A. H., Young, M. B., Zisook, S., Malievskaia, E.
Open Accessindividual

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study

This Phase I/II study (n=52) tested a group retreat model of psilocybin therapy for people with metastatic cancer and anxiety or depression, using 25 mg psilocybin in a 3-day retreat format. No unattended distress episodes occurred, and anxiety and depression scores fell over 28 days.

Published
Journal
Psychedelic Medicine
Authors
Back, A. L., McGregor, B. A., Thorn, L. L., Baker, K., Gooley, T., Kaelen, M., Harvey, K., Guy, J. M., Myers, S., Perez, J., Thompson, P., Billingsley, L., Sesnon, C.
Paywallindividual

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression

This re-analysis of the COMPASS Phase IIb trial (n=233) investigates the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcomes in treatment-resistant depression. Participants received a single dose of 25, 10, or 1 mg of psilocybin (COMP360) with psychological support. Higher doses produced stronger psychedelic effects, and reductions in depression (MADRS scores) at Week 3 correlated most strongly with dimensions of Oceanic Boundlessness (r = −0.508), Visual Restructuralization (r = −0.516), and Emotional Breakthrough Inventory (r = −0.637). Findings suggest the quality and intensity of psychedelic experiences mediate therapeutic outcomes and support dose-response mechanisms.

Published
Journal
Journal of Affective Disorders
Authors
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Carhart-Harris, R., Chai-Rees, J., Croal, M., Debattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Kirlic, N., Licht, R. W., Marwood, L., Meyer, T. D., Mistry, S., Nowakowska, A., Páleníček, T., Repantis, D., Schoevers, R. A., Simmons, H., Somers, M., Teoh, E., Tsai, J., Wahba, M., Williams, S., Young, A. H., Young, M. B., Zisook, S., Malievskaia, E.
Open Accessindividual

Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation

In a naturalistic, open‑label study a single high dose of psilocybin with psychotherapy produced sustained reductions in depression, anxiety, PTSD symptoms and neuroticism, and increases in openness and conscientiousness at three months. The size of these benefits was moderated by participants’ subjective dosing experiences (mystical‑type experiences, emotional breakthrough and post‑treatment growth) and demographic factors, highlighting variables that may help optimise psilocybin‑assisted treatment.

Published
Journal
Psychopharmacology
Authors
Irrmischer, M., Puxty, D. J., Deijen, J. B., Engelbregt, H., Yildirim, B. O.
Open Accessindividual

Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder

In a phase 2 double‑blind randomized trial comparing psilocybin therapy with escitalopram for moderate‑to‑severe major depressive disorder, acute subjective experiences—particularly mystical experiences and ego dissolution—uniquely mediated the superior antidepressant response to psilocybin over a six‑week period. Emotional breakthrough and intense music‑evoked responses were also associated with greater symptom improvement, providing qualified support that acute psychological experiences may be causal mechanisms in psilocybin’s antidepressant effects.

Published
Journal
International Journal of Mental Health and Addiction
Authors
Weiss, B., Leor Roseman, •., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., Erritzoe, D., Roseman, L.

Quick Facts

Full Name
Emotional Breakthrough Inventory
Domain
Mystical Experience
Papers Indexed
7
Score Range
6–30
Interpretation
Higher = better
Unit
points
All Measures